Healthcare CRM Market Worth $17.4 Billion by 2023 - Exclusive Report by MarketsandMarkets™9/30/2021 According to the new market research report "Healthcare CRM Market by Component (Software, Service), Delivery (On premise, Cloud, Public, Private, Hybrid), End user (Hospital, ASC, Payers, Life Science), Functionality (CSS, Marketing, Sales, Digital Marketing, AI, Analytics) - Global Forecast to 2023", published by MarketsandMarkets™, the Healthcare CRM Market is projected to reach USD 17.4 billion by 2023 from USD 8.8 billion in 2018, at a CAGR of 14.6% during the forecast
Browse in-depth TOC on "Healthcare CRM Market" 62 - Tables 34 - Figures 121 - Pages Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=88873203 The benefits of CRM software and a growing focus on patient engagement are the major factors driving the growth of the Healthcare CRM Market. Healthcare providers are expected to dominate the healthcare CRM end-user market in 2018 Based on end user, the Healthcare CRM Market is segmented into healthcare providers, the life sciences industry, and healthcare payers. The healthcare providers segment is estimated to account for the largest share of the Healthcare CRM Market in 2018. This segment is also expected to register the highest CAGR during the forecast period. Healthcare providers need to interact with multiple stakeholders, including patients, physicians, other referral healthcare organizations, healthcare payer organizations, pharmaceutical companies, and consumers/potential patients, and each requires unique CRM strategies and solutions. Moreover, there is a growing focus on patient engagement, which is again likely to drive the market for this segment. Healthcare CRM services to grow at the highest CAGR during 2018-2023 On the basis of component, the Healthcare CRM Market is segmented into software and services. The services segment is expected to dominate the Healthcare CRM Market in 2018. This segment is also expected to register the highest CAGR during the forecast period. Services form a large component of the Healthcare CRM Market primarily due to the indispensable role of service providers when it comes to the use of CRM solutions for healthcare. In terms of IT usage and skills, the healthcare industry is still in the nascent stage; it relies heavily on service providers for CRM-related services and support services, such as implementation, integration, training and education, maintenance, and technology upgrades. The recurring need for services such as software upgrades and maintenance is the key factor supporting the growth of this segment. Request for Sample Report -https://www.marketsandmarkets.com/requestsampleNew.asp?id=88873203 North America to dominate the market, followed by Europe Geographically, the global Healthcare CRM Market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is estimated to hold the largest share of the Healthcare CRM Market. Some of the major factors driving the growth of this market include government initiatives and regulations to encourage the adoption of healthcare IT, growing pressure on healthcare organizations to focus on patient engagement for patient retention, growing EHR adoption, growing focus of CRM providers on developing and commercializing AI and analytics-powered advanced CRM solutions, and the increasing number of ACOs. However, the market in Asia is estimated to grow at the highest CAGR during the forecast period. Factors such as the improving quality of healthcare, improvements in healthcare systems, the growing medical tourism market in Asian countries, and increasing government initiatives are the key factors driving the growth of this market. The key players in the Healthcare CRM Market are Salesforce.com, Inc. (US), SAP SE (Germany), Oracle (US), Microsoft (US), IBM (US), Influence Health (US), SugarCRM (US), Accenture (Ireland), Healthgrades (US), and Infor, Inc. (US). Browse Related Reports: Healthcare EDI Market by Component (Solution, Service), Delivery Mode (On-premise & Cloud, Mobile) Transaction Type (Claims Management, Payment Remittance, Payments, Healthcare Supply Chain), End-User - Global Forecast to 2025https://www.marketsandmarkets.com/Market-Reports/healthcare-edi-market-130571438.htmlRevenue Cycle Management/RCM Market by Product & Services (Eligibility Verification, Clinical Coding, CDI, Claims Processing, Denial Management, Outsourcing Services, Cloud), End User(Payers, Hospitals, Outpatient), Covid-19 Impact - Global Forecast to 2026https://www.marketsandmarkets.com/Market-Reports/revenue-cycle-management-market-153900104.html
0 Comments
According to the new market research report "Animal Antibiotics and Antimicrobials Market by Product (Tetracycline, Penicillin, Sulfonamide, Macrolide, Cephalosporin, Lincosamide), Mode of Delivery (Premixes, Oral Solution, Injection), Animal (Food producing & Companion) - Global Forecast to 2026", published by MarketsandMarkets™, the global Animal Antimicrobials Market is projected to reach USD 5.6 billion by 2026 from USD 4.7 billion in 2021, at a CAGR of 3.6% from 2021 to 2026.
Browse in-depth TOC on "Animal Antibiotics and Antimicrobials Market" 151 – Tables 35 – Figures 152 – Pages Download PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=25161353 The animal antibiotics market growth can largely be attributed to the rising demand for animal-derived food products, increasing incidence of zoonotic diseases, and the implementation of regulations to prevent the spread of animal diseases. Rising animal healthcare spending and the growing demand for pet insurance are further expected to drive the growth of this market. The untapped emerging markets such as China, India, and Brazil and growth in the overall companion animal population are also expected to offer significant growth opportunities to market players in the coming years. However, the limited number of new antibiotics, growing resistance to antimicrobials and antibiotics, and increasing good husbandry and hygiene practices are expected to hinder the growth of this market to a certain extent. The Tetracyclines segment accounted for the largest market share in 2020. Based on products, the global animal antimicrobials and antibiotics market is segmented into tetracyclines, penicillins, sulfonamides, macrolides, aminoglycosides, lincosamides, fluoroquinolones, cephalosporins, and other antimicrobial and antibiotic products. In 2020, the tetracyclines segment accounted for 48.9% of the global animal antimicrobials market. Tetracyclines exhibit advantages such as the highest potency against pathogenic microorganisms, are well-absorbed, show low toxicity, and are relatively inexpensive compared to other animal antimicrobial and antibiotic products. These advantages contribute to the large share of this product segment. The fluoroquinolones segment is expected to grow at the highest CAGR of 8.0% during the forecast period. Advantages such as higher efficacy at low concentrations, quick penetration through tissues, and the availability of variations in the route of administration result in the higher adoption of fluoroquinolones among end users. The Premixes segment accounted for the largest market share in 2020. Based on the mode of delivery, the global animal antimicrobials and antibiotics market is segmented into premixes, oral powders, oral solutions, injections, and other modes of delivery. In 2020, the premixes segment accounted for the largest share of 46.3% of the global animal antibiotics market. The large share of this segment can be attributed to the advantages of premixes, such as simplified mode of administration and lower instability and hygroscopicity of formulations. The injections segment is expected to witness the highest CAGR of 4.9% during the forecast period. Advantages such as immediate delivery of drugs and rapid onset of drug effects are expected to drive growth in this market. The food producing animal segment accounted for the largest market share in 2020. Based on animal type, the global animal antimicrobials and antibiotics market is categorized into food-producing animals and companion animals. In 2020, the food-producing animals segment accounted for the largest share of around 73.4%. This segment is also expected to register the highest CAGR of 3.9% during the forecast period. The large share of this segment is mainly due to the rising demand for animal-derived food products, increase in animal healthcare expenditure, and greater concerns about zoonotic diseases. Request Sample Pages: -https://www.marketsandmarkets.com/requestsampleNew.asp?id=25161353 North America was the largest regional market for animal antibiotics market in 2020 The animal antimicrobials and antibiotics market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of 30.3% of the global animal antimicrobials market. The large share of this region is mainly due to the increase in the region's animal population, rising demand for animal-derived food products, growth in pet insurance, and rising animal health expenditure compared to other regions. The Asia Pacific region is projected to grow at the highest CAGR of 5.4% during the forecast period. Factors such as the rapidly increasing animal population and rising demand for animal-derived food products are driving the growth of this market in the APAC. Some of the prominent players in the animal antimicrobials and antibiotics market are Boehringer Ingelheim (Germany), Zoetis Inc. (US), Elanco Animal Health (US), Merck & Co. Inc (US), Phibro Animal Health (US), Virbac (France), Vetoquinol S.A. (France), Ceva Santé Animale (France), Dechra Pharmaceuticals Plc (UK), Kyoritsu Seiyaku (Japan), Tianjin Ringpu (China), HIPRA (Spain), Zydus Animal Health (US), China Animal Husbandry (China), and Inovet (Belgium). Browse Related Reports: Animal Growth Promoters and Performance Enhancers Market by Product Antibiotic and Non-antibiotic (Hormones, Acidifiers, Feed Enzymes, Probioitcs & Prebiotics, Phytogenics), Animal (Poultry, Porcine, Livestock, Aquaculture) - Global Forecast to 2024 https://www.marketsandmarkets.com/Market-Reports/animal-growth-promoters-performance-enhancers-market-137134167.html Stem Cell Therapy Market worth $401 million by 2026 - Exclusive Report by MarketsandMarkets™9/28/2021 According to the new market research report "Stem Cell Therapy Market by Type (Allogeneic, Autologous), Therapeutic Application (Musculoskeletal, Wound & Injury, CVD, Autoimmune & Inflammatory), Cell Source (Adipose tissue, Bone Marrow, Placenta/Umbilical Cord) - Global Forecasts to 2026", published by MarketsandMarkets™, the global market is projected to reach USD 401 million by 2026 from USD 187 million in 2021, at a CAGR of 16.5% during the forecast period.
Browse and in-depth TOC on "Stem Cell Therapy Market" 142 - Tables 45 - Figures 160 - Pages Download PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=48 The Market growth is driven mainly by factors such as increasing investment in stem cell research and the rising number of GMP-certified stem cell manufacturing plants. However, factors such as ethical concerns and the high cost of stem cell research and manufacturing process likely to hinder the growth of this market. The adipose tissue-derived MSCs segment accounted for the largest share of the cell source segment in the Stem Cell Therapy Market in 2020. Based on the cell source from which stem cells are obtained, the global market is segmented into four sources. These include adipose tissue-derived MSCs (mesenchymal stem cells), bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources (which includes human corneal epithelium stem cells, peripheral arterial-derived stem cells, and induced pluripotent stem cell lines). In 2020, adipose tissue-derived MSCs accounted for the markets largest share due to their increasing utilization in treating inflammatory diseases and wounds & injuries. There are several associated advantages, such as ease of harvesting stem cells by minimally invasive methods, simplicity of the isolation procedure, and better quality & proliferation capacity of adipose tissue-derived stem cells. The musculoskeletal disorders segment accounted for the largest share of the therapeutic application segment in the Stem Cell Therapy Market in 2020 Based on therapeutic application, the global market is segmented into musculoskeletal disorders, wounds & injuries, cardiovascular diseases, surgeries, inflammatory & autoimmune diseases, neurological disorders, and other therapeutic applications (which include ocular diseases, fat loss, and peripheral arterial diseases). In 2020, the musculoskeletal disorders segment accounted for the largest share of the therapeutic application segment. The large market share of this segment is attributed to the increasing prevalence of musculoskeletal disorders such as osteoarthritis, bone repair, and regeneration Request Sample Pages:-https://www.marketsandmarkets.com/requestsampleNew.asp?id=48 The Asia Pacific region is the fastest-growing region of the Stem Cell Therapy Market in 2020. The Asia Pacific region is estimated to grow at the highest CAGR in the market during the forecast period. Some of the major factors fueling the growth of the APAC market include regulatory approvals and guidelines for product approvals and the presence of major stem cell players in countries such as South Korea, Japan, India, and Australia. Key players in the Stem Cell Therapy Market include Smith & Nephew (UK), MEDIPOST Co., Ltd. (South Korea), Anterogen Co., Ltd. (South Korea), PHARMICELL Co., Ltd. (South Korea), JCR Pharmaceuticals Co., Ltd. (Japan), and NuVasive, Inc. (US). Browse Related Reports: Nerve Repair and Regeneration Market by Products (Nerve Conduits, Nerve Wraps, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Spinal Cord Stimulation, TENS, TMS), Application (Neurorrhaphy, Nerve Grafting, Stem Cell Therapy) - Global Forecast to 2025 https://www.marketsandmarkets.com/Market-Reports/nerve-repair-regeneration-market-883.html According to a new market research report " Medical Image Analysis Software Market by Type (Standalone), Images (2D, 3D, 4D), Modality (CT, MRI, PET, Ultrasound), Application (Orthopedic, Dental, Oncology, Nephrology), End User (Hospital, Diagnostic Centre, Research) - Global Forecasts to 2022", published by MarketsandMarkets™, the market is expected to reach USD 3.88 Billion by 2022 from USD 2.61 Billion in 2017, at a CAGR of 8.2% during the forecast period.
Browse in-depth TOC on " Medical Image Analysis Software Market " 303 – Tables 43 – Figures 313 – Pages Download PDF Brochure:- http://www.marketsandmarkets.com/pdfdownload.asp?id=846 The growth of the market is attributed to technological advancements in medical imaging systems & analysis software, growing public- and private-sector investments in the medical imaging market, increasing use of imaging equipment due to rising prevalence of chronic diseases, fusion of imaging technologies, and growing applications of computer-aided diagnosis. Growing need for automated image analysis tools, rising adoption of cloud-based imaging solutions, and untapped emerging markets are expected to offer significant growth opportunities for manufacturers in the coming years. Integrated software to dominate the market in 2017 Based on type, the Medical Image Analysis Software Market is segmented into integrated and standalone software. In 2017, the integrated software segment is expected to account for the largest share of the Medical Image Analysis Software Market. The compatibility of the software with the equipment is examined by the manufacturer beforehand and easy handling and fast processing are additional factors that contribute to the adoption of integrated image analysis software. However, the standalone software segment is expected to grow at the highest CAGR during the forecast period. Standalone software offers high flexibility and easy-to-use tools to inspect, evaluate, and process imaging data. These advantages are driving its growth in the market. On the basis of end user, hospitals are projected to grow at the highest CAGR By end user, the Medical Image Analysis Software Market is segmented into hospitals, diagnostic centers, and research centers. Hospitals are expected to register the highest CAGR during the forecast period. The greater use of medical imaging software in hospitals & the higher installed base of diagnostic imaging systems (as compared to diagnostic and research centers) and high patient inflow (as compared to diagnostic centers) are expected to boost the demand for medical image analysis software in this segment. North America to dominate the market followed by Europe In 2017, North America is expected to account for the largest share of the market. The high growth of the North American market is attributed to the factors such as the growing geriatric population, high incidence/prevalence of various diseases, the large number of imaging centers in this region, ongoing research, fast adoption of technologically advanced imaging systems, and increasing awareness about the benefits of early disease diagnosis. In 2017, Europe is expected to hold the second largest share of this market. Talk To Our Research Analysts: -http://www.marketsandmarkets.com/speaktoanalyst.asp?id=846 Factors such as rising incidence of chronic diseases and injuries, increasing demand for non-radiation diagnostic solutions, technological advancements and new product launches, large number of ongoing research activities, and increasing government and public-private investments are expected to fuel the market growth in this region. The Medical Image Analysis Software Market is highly competitive with the presence of several small and big players. Some of the players in the Medical Image Analysis Software Market include AGFA Healthcare (Belgium), AQUILAB (France), Carestream Health, Inc. (US), Esaote S.p.A (Italy), GE Healthcare (US), Image Analysis (UK), INFINITT Healthcare Co, Ltd. (South Korea), Merge Healthcare, Inc. (US), MIM Software Inc. (US), Mirada Medical Limited (UK), Philips Healthcare (Netherlands), ScienceSoft USA Corporation (US), Siemens Healthineers (Germany), Toshiba Medical Systems Corporation (Japan), and Xinapse Systems Ltd (UK). Blood Screening Market Worth $3.5 Billion by 2025 - Exclusive Report by MarketsandMarkets™9/26/2021 According to the new market research report "Blood Screening Market by Technology (Nucleic Acid Amplification, (Real Time PCR), ELISA (Chemiluminescence immunoassay), Rapid Test, Western Blot), Product (Instrument, Reagent & Kits, Software) & End User (Blood Bank, Hospital) - Global Forecast to 2025", published by MarketsandMarkets™, the Blood Screening Market is projected to reach USD 3.5 billion by 2025 from USD 1.9 billion in 2020, at a CAGR of 12.8%.
Browse in-depth TOC on "Blood Screening Market" 372 – Tables 31 – Figures 153 – Pages Request for PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=267747042 The increasing demand for donated blood, the rising number of blood donations, the growing prevalence of infectious diseases, and the increasing prevalence of newer pathogens are the key factors driving the growth of this market. The reagents & kits segment accounted for the largest share of the market, by product & service, in 2019 Based on product & service, the Blood Screening Market is segmented into reagents and kits, instruments, and software and services. The reagents and kits segment accounted for the largest share of the market in 2019. The large share of this segment can be attributed to the high consumption and repeated use of reagents & kits in blood screening procedures. Also, the accessibility of a wide range of reagents and the need for reliable, specific, and fast detection of TTIs are driving the growth of the blood screening reagents & kits market. Blood banks segment to register the highest growth rate during the forecast period Based on end users, the Blood Screening Market is segmented into blood banks and hospitals. The blood bank segment accounted for the larger market share in 2019 and is projected to witness a higher growth rate during the forecast period. This can be attributed to the increasing demand for donated blood, a growing number of organ transplantation surgeries, rising awareness regarding the safety of blood, an increasing number of donations worldwide, and growth in government funding to charitable trusts. North America is the largest regional market for blood screening Based on region, the market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. In 2019, North America accounted for the largest market share, followed by Europe. Factors such as the increasing demand for donated blood, the rising number of blood donations, the growing prevalence of infectious diseases, and the increasing prevalence of newer pathogens, the presence of high-quality infrastructure for hospitals and clinical laboratories, and the presence of major market players in the region are driving the growth of the Blood Screening Market in North America. Get 10% Customization on this Research Report:- https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=267747042 The prominent players operating in the Blood Screening Market include Grifols (Spain), F. Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), BioMérieux (France), Bio-Rad Laboratories (US), Siemens Healthineers (Germany), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US) ,Ortho Clinical Diagnostics, Inc.(US), Becton, Dickinson and Company (US), DiaSorin (Italy), GFE (Germany), Trinity Biotech (Ireland), Merck Millipore (Germany), GE Healthcare (US), Perkin Elmer (US), Bio-Techne Corporation (US), and J Mitra & Co. Pvt. Ltd (India). Browse Related Report: In-Vitro Diagnostics Market by Product & Service (Instrument, Kits), Technology (Immunoassay, MDx, Hematology, Urinalysis), Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) End User (Hospitals) - Global Forecast to 2025 https://www.marketsandmarkets.com/Market-Reports/ivd-in-vitro-diagnostics-market-703.html Mycoplasma Testing Market by Product & Service (Assays, Kits, Reagents), Technique (NAT, ELISA, Staining), Application (Cell Line, End of Production Testing), End User (Biopharmaceutical, Cell Banks, CROs), Region - Global Forecast to 2025https://www.marketsandmarkets.com/Market-Reports/mycoplasma-testing-market-136509856.html In-Vitro Diagnostics Market worth $96.0 billion by 2025 - Exclusive Report by MarketsandMarkets™9/23/2021 According to the new market research report "In-Vitro Diagnostics Market by Product & Service (Instrument, Kits), Technology (Immunoassay, MDx, Hematology, Urinalysis), Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) End User (Hospitals) - Global Forecast to 2025", published by MarketsandMarkets™, the global IVD Market size is projected to reach USD 96.0 billion by 2025 from USD 84.5 billion in 2020, at a CAGR of 2.6% during the forecast period.
Browse in-depth TOC on "In-Vitro Diagnostics Market" 262 – Tables 53 – Figures 359 – Pages Download PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=703 Factors such as the increased adoption of PoC IVD devices, rising elderly population base, and the growing number of infectious diseases are expected to drive the growth of the IVD Market. By-products and services, the reagents & kits segment is expected to dominate the in vitro diagnostics market in 2020 Based on products and services, the IVD Market has been segmented into regents and kits, instruments, data management software and services. Within market, reagents and kits accounted for the largest share in 2020. The large share of this segment can be attributed to the superior quality of reagents enabling accurate diagnosis and thus, having high preference amongst the healthcare professionals. By end user, a point-of-care testing segment is expected to grow at the highest CAGR in the in vitro diagnostics market during the forecast period Based on end user, the market has been segmented into hospitals, laboratories, patient self-testing, academia, point-of-care -testing others. The point-of-care testing segment is estimated to have enormous growth due to rising availability of highly efficient PoC kits. Recently launched point-of-care devices offer a precise diagnosis of chronic diseases that has raised its adoption in laboratories. Get 10% Customization on this Research Report: -https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=703 North America holds the largest share in the market in 2020, followed by Europe North America dominates the overall IVD Market based on region. This can be attributed to the rising geriatric population. Elderly population has comparatively weaker immunity and, therefore, is more susceptible to infections and other diseases. Furthermore, the regulatory scenario is quite stringent in the region that ensures the availability of defect-free IVD devices in the market that proves beneficial for market growth. The prominent players in the in vitro diagnostics market include Roche Diagnostics Limited (Switzerland), Siemens Healthineers (Germany), Danaher Corporation (US), Abbott Laboratories (US), Thermo Fisher Scientific (US), Johnson & Johnson (US), Becton, Dickinson and Company (US), Bio-Rad Laboratories (US), Sysmex Corporation (Japan), bioMérieux (France), Diasorin (Italy), Ortho-Clinical Diagnostics (US), and Qiagen (Germany). Browse Related Reports: US In Vitro Diagnostics (IVD) Market by Technology (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Microbiology), Application (Infectious Diseases, Diabetes, Cancer, Cardiology), End User (Hospitals & Laboratories) & by Region - Forecast to 2020https://www.marketsandmarkets.com/Market-Reports/u-s-in-vitro-diagnostics-market-66290979.html According to the new market research report " Flow Cytometry Market by Technology (Cell-based, Bead-based), Product (Analyzer, Sorter, Reagents, Consumables, Software), End user (Academia, Research Labs, Hospitals, Clinical Laboratories, Pharma-Biotech Cos), Application - Global Forecasts to 2025", published by MarketsandMarkets™, the Flow Cytometry Market is projected to reach USD 6.4 billion by 2025 from USD 4.0 billion in 2019, at a CAGR of 8.3%.
Browse in-depth TOC on "Flow Cytometry Market" 204 – Tables 40 – Figures 248 – Pages Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65374584 The major factors driving the growth of the Flow Cytometry Market are the technological advancements in flow cytometers, increasing adoption of flow cytometry techniques in research activities & clinical trials, the growing focus on immunology and immuno-oncology research, increasing incorporation of AI platforms in flow cytometry workflows & advancements in flow cytometry software, high incidence and prevalence of HIV-AIDS & cancer, and availability of novel application-specific flow cytometry products. The bead-based flow cytometry segment is expected to grow at the highest CAGR during the forecast period On the basis of technology, the global market is segmented into cell-based and bead-based flow cytometry. The bead-based flow cytometry segment is estimated to witness the highest growth during the forecast period. This technology offers various procedural advantages over other cell-based assays, such as the capacity to detect multiple analytes (also known as multiplexing), high reproducibility, stability, and speed. Reagents and consumables are expected to hold the largest share of the market in 2019 The market is segmented on the basis of products and services into reagents and consumables, instruments, services, software, and accessories. The reagents and consumables segment is expected to command the largest share of the global market in 2019. Factors such as the development and commercialization of high-quality application-specific reagents and assays and the continuous requirement of flow cytometry reagents by end users (due to the increasing number of flow cytometry-based research activities) are expected to drive the growth of the reagents and consumables market in the coming years. Get 10% Customization on this Research Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=65374584 North America is expected to dominate the Flow Cytometry Market in 2019 Geographically, the market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America is expected to account for the largest share of the global market in 2019. The favorable business environment, continuously growing number of research activities, the rising number of drug discovery initiatives by US-based pharmaceutical & biotechnology companies, and the strong presence of key players are factors propelling the growth of the North American flow cytometry industry. The major players operating in the Flow Cytometry Market are Becton, Dickinson and Company (US), Beckman Coulter, Inc. (US), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Sysmex Partec GmbH (Germany), Luminex Corporation (US), Miltenyi Biotec GmbH (Germany), Bio-Rad Laboratories, Inc. (US), Sony Biotechnology, Inc. (US), Agilent Technologies, Inc. (US), bioMérieux S.A. (France), Enzo Life Sciences, Inc. (US), Stratedigm, Inc. (US), Cytonome/ST LLC (US), Cytek Biosciences (US), and Apogee Flow Systems Ltd. (UK). Browse Related Reports: Cell Analysis Market by Product [Microscope, Spectrophotometers, Flow cytometry (Software, Accessories)], Process (Cell Viability, Cell Proliferation, Signal Transduction), End User (Pharma, Research, Biotechnology Companies) - Global Forecast to 2024 Stem Cell Therapy Market worth $401 million by 2026 - Exclusive Report by MarketsandMarkets™9/21/2021 According to the new market research report "Stem Cell Therapy Market by Type (Allogeneic, Autologous), Therapeutic Application (Musculoskeletal, Wound & Injury, CVD, Autoimmune & Inflammatory), Cell Source (Adipose tissue, Bone Marrow, Placenta/Umbilical Cord) - Global Forecasts to 2026", published by MarketsandMarkets™, the global market is projected to reach USD 401 million by 2026 from USD 187 million in 2021, at a CAGR of 16.5% during the forecast period.
Browse and in-depth TOC on "Stem Cell Therapy Market" 142 - Tables 45 - Figures 160 - Pages Download PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=48 The Market growth is driven mainly by factors such as increasing investment in stem cell research and the rising number of GMP-certified stem cell manufacturing plants. However, factors such as ethical concerns and the high cost of stem cell research and manufacturing process likely to hinder the growth of this market. The adipose tissue-derived MSCs segment accounted for the largest share of the cell source segment in the Stem Cell Therapy Market in 2020. Based on the cell source from which stem cells are obtained, the global market is segmented into four sources. These include adipose tissue-derived MSCs (mesenchymal stem cells), bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources (which includes human corneal epithelium stem cells, peripheral arterial-derived stem cells, and induced pluripotent stem cell lines). In 2020, adipose tissue-derived MSCs accounted for the markets largest share due to their increasing utilization in treating inflammatory diseases and wounds & injuries. There are several associated advantages, such as ease of harvesting stem cells by minimally invasive methods, simplicity of the isolation procedure, and better quality & proliferation capacity of adipose tissue-derived stem cells. The musculoskeletal disorders segment accounted for the largest share of the therapeutic application segment in the Stem Cell Therapy Market in 2020 Based on therapeutic application, the global market is segmented into musculoskeletal disorders, wounds & injuries, cardiovascular diseases, surgeries, inflammatory & autoimmune diseases, neurological disorders, and other therapeutic applications (which include ocular diseases, fat loss, and peripheral arterial diseases). In 2020, the musculoskeletal disorders segment accounted for the largest share of the therapeutic application segment. The large market share of this segment is attributed to the increasing prevalence of musculoskeletal disorders such as osteoarthritis, bone repair, and regeneration Request Sample Pages:-https://www.marketsandmarkets.com/requestsampleNew.asp?id=48 The Asia Pacific region is the fastest-growing region of the Stem Cell Therapy Market in 2020. The Asia Pacific region is estimated to grow at the highest CAGR in the market during the forecast period. Some of the major factors fueling the growth of the APAC market include regulatory approvals and guidelines for product approvals and the presence of major stem cell players in countries such as South Korea, Japan, India, and Australia. Key players in the Stem Cell Therapy Market include Smith & Nephew (UK), MEDIPOST Co., Ltd. (South Korea), Anterogen Co., Ltd. (South Korea), PHARMICELL Co., Ltd. (South Korea), JCR Pharmaceuticals Co., Ltd. (Japan), and NuVasive, Inc. (US). Browse Related Reports: Nerve Repair and Regeneration Market by Products (Nerve Conduits, Nerve Wraps, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Spinal Cord Stimulation, TENS, TMS), Application (Neurorrhaphy, Nerve Grafting, Stem Cell Therapy) - Global Forecast to 2025 https://www.marketsandmarkets.com/Market-Reports/nerve-repair-regeneration-market-883.html According to the new market research report "Nucleic Acid Isolation and Purification Market by Product (Kit, Reagent, Instrument), Method (Column, Magnetic Beads), Type (Genomic DNA, Plasmid DNA, miRNA), Application (Drug Discovery, Precision Medicine), End User (Academic) - Global Forecast to 2025", published by MarketsandMarkets™, the global Nucleic Acid Isolation and Purification Market is projected to reach USD 4.8 billion by 2025 from USD 3.2 billion in 2020, at a CAGR of 8.9% during the forecast period.
Browse in-depth TOC on "Nucleic Acid Isolation and Purification Market" 116 – Tables 34 – Figures 191 – Pages Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=229978287 The growth of this market can mainly be attributed to the increasing R&D activities as well as technological advancements and increasing automation. On the other hand, the high cost of automated instruments is expected to hinder the growth of the market. By product, the kits segment accounted for the largest market share in 2019. On the basis of product, the nucleic acid isolation and purification market has been segmented into kits, reagents, and instruments. The kits segment accounted for the largest share of the global nucleic acid isolation and purification market in 2019. Growth in this market can be attributed to the low cost and easy usage of kits in applications such as gene sequencing, molecular diagnostics, and gene cloning. By application, the diagnostics segment accounted for the largest market share in 2019. On the basis of application, the global nucleic acid isolation and purification market is segmented into diagnostics, drug discovery & development, personalized medicine, agriculture & animal research, and other applications. In 2019, the diagnostics segment accounted for the largest share of the global nucleic acid isolation and purification market; this segment is also expected to register the highest CAGR during the forecast period. The large share and high growth rate of this segment can be attributed to the growing awareness of genomic diagnostics among patients and the increasing efficiency of genomics sequencing in the diagnosis of diseases. By Type, the plasmid DNA isolation and purification segment accounted for the largest market share in 2019. On the basis of type, the global nucleic acid isolation and purification market is segmented into plasmid DNA isolation and purification, total RNA isolation and purification, circulating nucleic acid isolation and purification, genomic DNA isolation and purification, messenger RNA isolation and purification, microRNA isolation and purification, PCR cleanup, and other nucleic acid isolation and purification types. In 2019, the plasmid DNA isolation segment accounted for the largest share of the market. The large share of this market segment can be attributed to the wide use of purified plasmid DNA in a variety of downstream applications, such as PCR, sequencing, expression of proteins, gene therapy, and transfection. Get 10% Customization on this Research Report :- https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=229978287 North America dominates the nucleic acid isolation and purification market during the forecast period. In 2019, North America accounted for the largest share of the nucleic acid isolation and purification market, followed by Europe. The large share of this region can be attributed to factors such as significant R&D spending in biotechnology and pharmaceutical companies, the large size of the biotechnology industry, technological advancements, and government support in the region. However, the Asia Pacific region is expected to grow at the highest rate during the forecast period QIAGEN N.V. (Netherlands), Thermo Fisher Scientific (US), and F. Hoffmann-La Roche Ltd. (Switzerland) are the key players operating in the nucleic acid isolation and purification market. Other prominent players in this market include Promega Corporation (US), Agilent Technologies (US), Bio-Rad Laboratories (US), Danaher Corporation (US), GE Healthcare (US), Illumina, Inc. (US), Merck KGaA (Germany), Takara Bio (Japan), Zymo Research (US), New England Biolabs (US), Norgen Biotek Corp (Canada), Omega Bio-tek (US), Genaxxon Bioscience GmbH (Germany), 3B BlackBio Biotech India Limited (India), Invitek Molecular (Germany), BioVision (US), and Analytik Jena AG (Germany). Browse Related Reports: Isothermal Nucleic Acid Amplification Technology/INAAT Market by Product (Assay & Kit, System), Application (Infectious disease [HIV, Influenza], Blood Screening), Type (LAMP, SDA, NASBA, HDA), End User, Region - Global Forecast to 2024 https://www.marketsandmarkets.com/Market-Reports/isothermal-nucleic-acid-amplification-technologies-inaat-market-839.html Genomics Market by Product & Service (System & Software, Consumables, Services), Technology (Sequencing, PCR), Application (Drug Discovery & Development, Diagnostic, Agriculture), End User (Hospital & Clinics, Research Centers) – Global Forecast to 2025 https://www.marketsandmarkets.com/Market-Reports/genomics-market-613.html According to the new market research report "High-Throughput Screening (HTS) Market by Product (Instruments, Software, Service), Technology (Cell-Based Assays, Label-Free), Application (Drug Discovery, Biochemical Screening, Research), End User (Pharma & Biotech, CROs)- Global Forecast to 2025", published by MarketsandMarkets™, the global High-Throughput Screening Market size is projected to reach USD 26.4 billion by 2025 from USD 15.3 billion in 2020, at a CAGR of 11.5% during the forecast period.
Browse in-depth TOC on "High-Throughput Screening (HTS) Market" 432 – Tables 40 – Figures 319 – Pages Download PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134981950 The HTS Market growth is driven mainly by factors such as increasing R&D spending by pharmaceutical & biotechnology companies, technological advancements in high-throughput screening market and the availability of government funding & venture capital investments. Emerging markets and growing applications in life sciences research are also factors expected to provide growth opportunities for players in the market. The consumables segment accounted for the largest share of the product & services segment in the high-throughput screening market in 2019. On the basis type of product & service, the HTS Market is broadly segmented into consumables , instruments, services, and software. In 2019, consumables accounted for the largest share of the high-throughput screening (HTS) market. This can primarily be attributed to the wide use of reagents & assay kits in HTS techniques, increasing pharmaceutical R&D, and rising government funding for life sciences research. The drug discovery segment accounted for the largest share of the application segment in the high-throughput screening market in 2019. Based on application, the HTS Market is categorized into four segments—drug discovery, biochemical screening, life sciences, and other applications. The drug discovery application segment accounted for the largest share of the market in 2019. The key factor driving this segments growth is the increasing number of clinical trials and rising pharmaceutical R&D expenditure. Request Sample Pages:-https://www.marketsandmarkets.com/requestsampleNew.asp?id=134981950 The Asia Pacific region is the fastest-growing region of the high-throughput screening market in 2019. In 2019, Asia Pacific region accounted for the fastest-growing region of the HTS Market. It is also estimated to grow at the highest CAGR in the market during the forecast period, this is mainly due to factors such as the rising R&D spending, growing public-private partnerships, and increasing government funding are factors driving the growth of the market in this region. Some of the prominent players in the high-throughput screening market are Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Danaher Corporation (US), PerkinElmer, Inc. (US), Tecan Group Ltd. (Switzerland), AXXAM S.p.A. (Italy), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Promega Corporation (US), Corning Incorporated (US), and Eurofins Scientific (Luxembourg). Browse Related Reports: Cell Analysis Market by Product [Microscope, Spectrophotometers, Flow cytometry (Software, Accessories)], Process (Cell Viability, Cell Proliferation, Signal Transduction), End User (Pharma, Research, Biotechnology Companies) - Global Forecast to 2024https://www.marketsandmarkets.com/Market-Reports/cell-analysis-market-157543946.html |
AuthorWe are providing and consulting the healthcare Industry Research Report. Archives
March 2022
Categories |